Lapatinib, a Dual EGFR and HER2 Kinase Inhibitor, Selectively Inhibits HER2-Amplified Human Gastric Cancer Cells and is Synergistic with Trastuzumab In vitro and In vivo
Clinical Cancer Research (2010) - Comments
doi: 10.1158/1078-0432.ccr-09-1112  issn: 1078-0432  issn: 1557-3265  pubmed: 20179222 

Zev A. Wainberg, Adrian Anghel, Amrita J. Desai, Raul Ayala, Tong Luo, Brent Safran, Marlena S. Fejzo, J. Randolph Hecht, Dennis J. Slamon, Richard S. Finn